The I-SPY2 TRIAL: Novel Trial Design for Development and Approval of Targeted Therapies (Early Stage Breast Cancer)
Friday, August 24, 2012
11:30 a.m. – 1:00 p.m.
Biodesign Institute Auditorium, ASU Tempe campus
Light refreshments will be provided
Laura J. Esserman, M.D., M.B.A., is a nationally prominent breast cancer surgeon/surgical oncologist at the University of California San Francisco. She is the director of the UCSF Carol Franc Buck Breast Care Center. Dr. Esserman leads the I-SPY2 TRIAL, a precompetitive consortium of academic, private sector and advocacy partners coordinated through the Foundation for the National Institutes of Health (NIH). I-SPY2 employs biomarker-driven adaptive design in neoadjuvant breast cancer to speed the evaluation of new drugs.
As principal investigator of a Department of Defense-funded Center of Excellence grant, she also brought together an extraordinary, multidisciplinary group of investigators and health care industry partners to address critical problems of breast cancer care. Her work is devoted to developing new, more innovative and effective ways to diagnose, treat, care for and empower breast cancer patients. Dr. Esserman has a special interest in integrating molecular biology and a health care learning system to deliver better personalized care and improved outcomes for breast cancer and all cancer patients.
Dr. Esserman earned an undergraduate degree from Harvard University and completed medical and surgical training at Stanford University. She completed a postdoctoral fellowship in breast oncology at Stanford University and earned a master’s degree at the Stanford School of Business.
Seminar sponsored by Arizona State University Complex Adaptive Systems Initiative and the Biodesign Institute
